Illumina Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Illumina Inc in the third quarter 2026?
Illumina Inc achieved a return on average equity (ROE) of 31.45 % in its third quarter 2026, this is above ILMN's average return on equity of 8.99%.
Illumina Inc s equity during the 12 months ending in the third quarter 2026 are valued at $2 billion

ROE has advanced compared to 31.08% in the second quarter 2026, due to net income growth.

Within the Laboratory Analytical Instruments industry only one company had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 186 to 324.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 27 2026) III. Quarter	(Jun 28 2026) II. Quarter	(Mar 29 2026) I. Quarter	(Dec 28 2025) IV. Quarter	(Sep 28 2025) III. Quarter
Y / Y Equity Change	32.09 %	25.69 %	13.01 %	14.75 %	-
Y / Y Net Income Change	46.67 %	-11.91 %	2.29 %	79.57 %	-78.72 %
Net Income (TTM) in Millions	895	825	853	850	702
Return On Equity (TTM)	31.45 %	31.08 %	33.99 %	34.94 %	29.94 %
ILMN's Total Ranking	# 324	# 186	# 262	# 111	#
Equity (TTM) in Millions	3,145	2,838	2,676	2,723	2,381
Seq. Equity Change	10.82 %	6.05 %	-1.73 %	14.36 %	5.45 %
Seq. Net Income Change	6.28 %	54.48 %	-59.88 %	122.67 %	-36.17 %

Back to ILMN Management Effectiveness >> ILMN's 5 Years Annual ROE >> Compare ILMN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 2
Sector	# 54
Overall	# 324

Return On Equity Statistics
High	Average	Low
55.11 %	8.99 %	-64.72 %
(Jun 29 2025)		(Jun 30 2024)

ILMN Annual Return On Equity	(Dec 28 2025) 2025	(Dec 29 2024) 2024	(Dec 31 2023) 2023	(Jan 01 2023) 2022	(Jan 02 2022) 2021
Total Equity in Millions	2,723	2,373	5,745	6,599	10,740
Y / Y Equity Change	14.75 %	-58.69 %	-12.94 %	-38.56 %	128.8 %
Net Income in Millions	850	-1,223	-1,161	-4,404	762
Y / Y Net Income Change	-	-	-	-	16.16 %
Return On Equity	31.22 %	-51.54 %	-20.21 %	-66.74 %	7.09 %

Back to ILMN Management Effectiveness >> ILMN's 5 Years Annual ROE >> Compare ILMN ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 31.22 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ILMN's' Return on Equity at Yahoo Finance
ILMN's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ILMN's Competitors
Subscribers only: Roe for Illumina Inc 's Suppliers
Subscribers only: Return On Equity for ILMN's Customers

Companies with similar Return On Equity at Sep 27 2026, within Healthcare Sector	ROE
Exelixis Inc	85.83 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %

Date modified: 2026-10-31T09:55:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.